Literature DB >> 7150868

The contractile effects of 5-hydroxytryptamine on the rat isolated vas deferens.

D W Hay, R M Wadsworth.   

Abstract

1 5-Hydroxytryptamine (5-HT) (5.16-1291 microM) produced a phasic contraction followed later by rhythmic contractions in the rat vas deferens, primarily in the epididymal half. 5-HT (129 microM) produced no response in Ca2+-free solution. Nifedipine (0.29 microM) or verapamil (2.04 microM) inhibited the initial phasic response to 5-HT, but inhibition of the rhythmic contractions required concentrations 5 fold (nifedipine) or 30 fold (verapamil) higher. 2 Methysergide (2.13 microM) abolished the phasic and reduced the frequency of the rhythmic contractions. Phentolamine (2.65 microM) did not affect the phasic response but reduced the amplitude of the rhythmic contractions. The combination of phentolamine (2.65 microM) and methysergide (2.13 microM) completely abolished the response to 5-HT (129 microM). 3 Desipramine (1.32 microM) had no effect on the phasic response to 5-HT (129 microM), but the rhythmic contractions were reduced in amplitude with no effect on their frequency. 4 In vasa deferentia removed from reserpine-treated or from guanethidine-denervated rats, both phasic and rhythmic components of the 5-HT (129 microM) contraction were augmented due to supersensitivity. 5 It is concluded that the phasic component of the 5-HT contraction is mediated by post-junctional 5-HT receptors, while the rhythmic component is mediated by the combination of post-junctional 5-HT receptors and noradrenaline released from neuronal stores. Assuming that nifedipine and verapamil are acting solely by inhibition of calcium channels, the phasic and rhythmic components of the 5-HT response may be mediated through separate Ca2+ channels. If this is correct, one channel might be a voltage-dependent channel and the other could be similar to, but distinct from the channel mediating the response to methoxamine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7150868      PMCID: PMC2044676          DOI: 10.1111/j.1476-5381.1982.tb09338.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Nonspecific denervation supersensitivity in the rat vas deferens "in vitro".

Authors:  Y Kasuya; K Goto; H Hashimoto; H Watanabe; H Munakata; M Watanabe
Journal:  Eur J Pharmacol       Date:  1969-11       Impact factor: 4.432

2.  Evidence against adrenergic motor transmission in the guinea-pig vas deferens.

Authors:  N Ambache; M A Zar
Journal:  J Physiol       Date:  1971-07       Impact factor: 5.182

3.  The guinea-pig isolated vas deferens: a method for increasing sensitivity to drugs.

Authors:  N B Thoa; G D Maengwyn-Davies
Journal:  J Pharm Pharmacol       Date:  1968-11       Impact factor: 3.765

4.  Differential effect of verapamil on excitation-contraction coupling in smooth muscle and on excitation-secretion coupling in adrenergic nerve terminals.

Authors:  G Haeusler
Journal:  J Pharmacol Exp Ther       Date:  1972-03       Impact factor: 4.030

5.  Mode of action of 5-hydroxytryptamine on isolated rat vas deferens.

Authors:  K Nishino; T Irikura; I Takayanagi
Journal:  Nature       Date:  1970-11-07       Impact factor: 49.962

6.  Supersensitivity of the nictitating membrane to 5-hydroxytryptamine and norepinephrine after various procedures.

Authors:  A R Wakade; R S Kanwar; O D Gulati
Journal:  J Pharmacol Exp Ther       Date:  1970-10       Impact factor: 4.030

7.  Ultrastructural cytochemistry and pharmacology of 5-hydroxytryptamine in adrenergic nerve endings. I. Localization of exogenous 5-hydroxytryptamine in the autonomic nerves of the rat vas deferens.

Authors:  G Jaim-Etcheverry; L M Zieher
Journal:  J Pharmacol Exp Ther       Date:  1969-04       Impact factor: 4.030

8.  The accumulation of C14-serotonin in the guinea-pig vas deferens.

Authors:  N B Thoa; D Eccleston; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1969-09       Impact factor: 4.030

9.  Presence of serotonin in the rat vas deferens: its influence on contractile responses.

Authors:  L Fuenmayor; J Gomez; H A Campos; E Romero
Journal:  Neuroscience       Date:  1976-06       Impact factor: 3.590

10.  The effects of drugs inhibiting catecholamine uptake on tyramine and noradrenaline-induced contractions of the isolated rat vas deferens.

Authors:  A Barnett; S Symchowicz; R I Taber
Journal:  Br J Pharmacol       Date:  1968-11       Impact factor: 8.739

View more
  6 in total

1.  Serotonin via 5-HT1B and 5-HT2B receptors stimulates anion secretion in the rat epididymal epithelium.

Authors:  G P Leung; S L Dun; N J Dun; P Y Wong
Journal:  J Physiol       Date:  1999-09-15       Impact factor: 5.182

2.  Evidence of 5-HT components in human sperm: implications for protein tyrosine phosphorylation and the physiology of motility.

Authors:  Francisco Jiménez-Trejo; Miguel Tapia-Rodríguez; Marco Cerbón; Donald M Kuhn; Gabriel Manjarrez-Gutiérrez; C Adriana Mendoza-Rodríguez; Ofir Picazo
Journal:  Reproduction       Date:  2012-10-01       Impact factor: 3.906

3.  Release of 5-hydroxytryptamine, dopamine and noradrenaline in the rat vas deferens in the presence of compound 48/80, veratridine or K+.

Authors:  S M Celuch; B D Sloley
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

4.  The effects of calcium channel inhibitors and other procedures affecting calcium translocation on drug-induced rhythmic contractions in the rat vas deferens.

Authors:  D W Hay; R M Wadsworth
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

5.  Regional distribution of dopamine, 5-hydroxytryptamine, and noradrenaline in the rat vas deferens.

Authors:  S M Celuch; B D Sloley
Journal:  Neurochem Res       Date:  1988-10       Impact factor: 3.996

6.  Cyclohexylamine, an active compound from Toddalia asiatica, contracts epididymal vas deferens via serotonergic receptors.

Authors:  Yuh-Fung Chen; Yu-Wen Wang; Ih-Sheng Chen; Huei-Yann Tsai
Journal:  Biomedicine (Taipei)       Date:  2020-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.